D
Dirk J. Richel
Researcher at University of Amsterdam
Publications - 51
Citations - 4347
Dirk J. Richel is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Cancer & Gemcitabine. The author has an hindex of 25, co-authored 51 publications receiving 4132 citations. Previous affiliations of Dirk J. Richel include VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol,Miriam Koopman,Annemieke Cats,C.J. Rodenburg,Geert Jan Creemers,Jolanda G Schrama,Frans L. G. Erdkamp,A. Vos,Cees J van Groeningen,Harm Sinnige,Dirk J. Richel,Emile E. Voest,Jeroen R. Dijkstra,Marianne E. Vink-Börger,Ninja Antonini,Linda Mol,Johan H. J. M. van Krieken,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life.
Journal ArticleDOI
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity
Louis Vermeulen,Matilde Todaro,F. De Sousa Mello,Martin R. Sprick,Kristel Kemper,M. Perez Alea,Dirk J. Richel,Giorgio Stassi,Jan Paul Medema +8 more
TL;DR: In this article, the authors show that spheroid cultures of these colon CSCs contain expression of CD133, CD166, CD44, CD29, CD24, Lgr5, and nuclear β-catenin, which have all been suggested to mark the cancer stem cell population.
Journal ArticleDOI
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler,Tatsuya Ioka,Dirk J. Richel,Jaafar Bennouna,Richard Letourneau,Takuji Okusaka,Akihiro Funakoshi,Junji Furuse,Young Suk Park,S. Ohkawa,Gregory M Springett,Harpreet Wasan,Peter C. Trask,Paul Bycott,Alejandro D. Ricart,Sinil Kim,Eric Van Cutsem +16 more
TL;DR: The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer, adding to increasing evidence that targeting of VEGF signalling is an ineffective strategy in this disease.
Journal ArticleDOI
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Joost J.C. Verhoeff,Olaf van Tellingen,An Claes,Lukas J.A. Stalpers,Myra E. van Linde,Dirk J. Richel,William P.J. Leenders,Wouter R. van Furth +7 more
TL;DR: Although angiogenesis inhibition is of considerable value for symptom reduction in GBM patients, lack of proof of a true anti-tumour effect raises concerns about the place of this type of therapy in the treatment of GBM.
Journal ArticleDOI
Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A.
Carina L. Bos,L. L. Kodach,G. R. van den Brink,Sander H. Diks,M. M. van Santen,Dirk J. Richel,Maikel P. Peppelenbosch,James C. H. Hardwick +7 more
TL;DR: In this paper, the effects of aspirin on the oncogenic Wnt/β-catenin pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of β-Catenin by immunoblotting.